The compounded medications are produced by a compounding pharmacy operating under applicable regulations, though Brello does not publicly disclose the pharmacy name, which limits independent verification
L- ,
For semaglutide, the relevant secondary patents include: Formulation patents covering the specific inactive ingredients, pH buffers, and stabilizers that keep semaglutide stable in solution (US 9,714,283, expires 2033) Method-of-use patents covering specific dosing schedules and titration protocols (US 10,195,214, expires 2032) Delivery device patents for the pen injector mechanism used in Ozempic and Wegovy (separate patent family, expires 2029-2031) Oral formulation patents for the SNAC (salcaprozate sodium) absorption enhancer used in Rybelsus tablets (US 9,931,349, expires 2032) The expiration date that matters to you depends on which formulation you care about
In cases of bleeding, treatment in the hospital may include intravenous proton pump inhibitors and surgery to stop the hemorrhage